Tech Company Financing Transactions

Gemini Therapeutics Funding Round

Gemini Therapeutics closed a $42.5 million Series A funding round on 10/18/2017. Investors included Atlas Venture, Lightstone Ventures and OrbiMed.

Transaction Overview

Company Name
Gemini Therapeutics
Announced On
10/18/2017
Transaction Type
Venture Equity
Amount
$42,500,000
Round
Series A
Investors

Atlas Venture (Lead Investor) (Jason Rhodes)

Lightstone Ventures (Lead Investor) (Jean George)

OrbiMed (Lead Investor) (Carl Gordon)

Proceeds Purpose
Gemini is developing first-in-class therapeutics built on the strong foundation of human genetics research in AMD, the leading cause of irreversible blindness in the U.S. and EU.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 One Kendall Sq. 3rd Floor
Cambridge, MA 02139
USA
Phone
(617) 401-4400
Website
www.geminitherapeutics.com
Email Address
[email protected]
Overview
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
Profile
Gemini Therapeutics LinkedIn Company Profile
Social Media
Gemini Therapeutics Company Twitter Account
Company News
Gemini Therapeutics News
Facebook
Gemini Therapeutics on Facebook
YouTube
Gemini Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jason Meyenburg
  Jason Meyenburg LinkedIn Profile  Jason Meyenburg Twitter Account  Jason Meyenburg News  Jason Meyenburg on Facebook
Chief Medical Officer
Sandra Rojas-Caro
  Sandra Rojas-Caro LinkedIn Profile  Sandra Rojas-Caro Twitter Account  Sandra Rojas-Caro News  Sandra Rojas-Caro on Facebook
Chief Technical Officer
Scott Lauder
  Scott Lauder LinkedIn Profile  Scott Lauder Twitter Account  Scott Lauder News  Scott Lauder on Facebook
Vice President
Walter Strapps
  Walter Strapps LinkedIn Profile  Walter Strapps Twitter Account  Walter Strapps News  Walter Strapps on Facebook
VP - R & D
Suresh Katti
  Suresh Katti LinkedIn Profile  Suresh Katti Twitter Account  Suresh Katti News  Suresh Katti on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/18/2017: MycoTechnology venture capital transaction
Next: 10/18/2017: Dave venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.